# Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)

> **NCT00412750** · PHASE3 · TERMINATED · sponsor: **Novartis** · enrollment: 159 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **DRUG:** Telbivudine (LdT)
- **DRUG:** peginterferon alpha-2a

## Key facts

- **NCT ID:** NCT00412750
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 159 (ACTUAL)
- **Why stopped:** Enrollment stopped for safety issues
- **Last updated:** 2011-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412750, "Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00412750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*